Research Programs Unit, Genome-Scale Biology, Biomedicum Helsinki, University of Helsinki, FI-00014 Helsinki, Finland.
Unit of Vitreoretinal Surgery, Ophthalmology, University of Helsinki and Helsinki University Hospital, FI-00014 Helsinki, Finland.
Int J Mol Sci. 2018 Dec 13;19(12):4034. doi: 10.3390/ijms19124034.
Diabetic retinopathy (DR) is the most common diabetic microvascular complication and major cause of blindness in working-age adults. According to the level of microvascular degeneration and ischemic damage, DR is classified into non-proliferative DR (NPDR), and end-stage, proliferative DR (PDR). Despite advances in the disease etiology and pathogenesis, molecular understanding of end-stage PDR, characterized by ischemia- and inflammation-associated neovascularization and fibrosis, remains incomplete due to the limited availability of ideal clinical samples and experimental research models. Since a great portion of patients do not benefit from current treatments, improved therapies are essential. DR is known to be a complex and multifactorial disease featuring the interplay of microvascular, neurodegenerative, metabolic, genetic/epigenetic, immunological, and inflammation-related factors. Particularly, deeper knowledge on the mechanisms and pathophysiology of most advanced PDR is critical. Lymphatic-like vessel formation coupled with abnormal endothelial differentiation and progenitor cell involvement in the neovascularization associated with PDR are novel recent findings which hold potential for improved DR treatment. Understanding the underlying mechanisms of PDR pathogenesis is therefore crucial. To this goal, multidisciplinary approaches and new ex vivo models have been developed for a more comprehensive molecular, cellular and tissue-level understanding of the disease. This is the first step to gain the needed information on how PDR can be better evaluated, stratified, and treated.
糖尿病视网膜病变(DR)是最常见的糖尿病微血管并发症,也是工作年龄段成年人失明的主要原因。根据微血管退行性变和缺血性损伤的程度,DR 分为非增殖性 DR(NPDR)和终末期增殖性 DR(PDR)。尽管在疾病病因和发病机制方面取得了进展,但由于理想临床样本和实验研究模型的有限可用性,终末期 PDR 以缺血和炎症相关新生血管形成和纤维化为特征的分子理解仍不完整。由于很大一部分患者不能从现有治疗中获益,因此需要改进治疗方法。DR 是一种复杂的多因素疾病,其特征是微血管、神经退行性、代谢、遗传/表观遗传、免疫和炎症相关因素的相互作用。特别是,对大多数晚期 PDR 的机制和病理生理学有更深入的了解至关重要。淋巴管样血管形成以及内皮细胞异常分化和祖细胞参与 PDR 相关的新生血管形成是最近的新发现,为改善 DR 治疗提供了潜力。因此,了解 PDR 发病机制的潜在机制至关重要。为此,已经开发了多学科方法和新的离体模型,以更全面地了解疾病的分子、细胞和组织水平。这是获得有关如何更好地评估、分层和治疗 PDR 所需信息的第一步。